To include your compound in the COVID-19 Resource Center, submit it here.

With $35M D round, EpicentRx aims to complete clinical testing of cancer immunotherapy

With a $35 million series D, EpicentRx hopes to take its immunotherapy through to an NDA and bring its oncolytic virus program to the clinic.

An undisclosed European investor was the sole investor in the round, which

Read the full 374 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers